Vitamin D supplementation and COVID‑19 risk: a population‑based, cohort study
Supplementation with cholecalciferol or calcifediol helped subject to achieve serum 25OHD levels ≥30 ng/ml which were associated with better COVID-19 outcomes.
Supplementation with cholecalciferol or calcifediol helped subject to achieve serum 25OHD levels ≥30 ng/ml which were associated with better COVID-19 outcomes.
This study recommends that people with darker skin supplement their diet with vitamin D3 through oral modes aiming to reduce the risk of adverse outcomes of...
Impact of daily high dose oral vitamin D therapy on the inflammatory markers
Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis. Take
COVID-19 severity in relation to sociodemographics and vitamin D use. Take Home
A high, single oral dose of 200,000 IU vitamin D3, compared to placebo, did not significantly reduce hospital length of stay in moderately to severely ill hospitalized patients diagnosed with COVID-19 in Brazil during the study period of June-August 2020.
This study did not find a benefit associated with vitamin D supplementation in COVID-19 patients but did identify that vitamin D deficiency may be a risk factor for higher in-patient mortality.
In this prospective study, the self-reported use of vitamin D supplements was associated with a lower risk of COVID-19 infection, independent of lifestyle, socio-economic status, prevalent chronic diseases and circulating...
Results from this retrospective analysis demonstrate that two consecutive doses of 200,000 IU cholecalciferol (total of 400,000 IU) can significantly improve the outcome in patients affected by COVID-19 that are also burdened with three or more...
In this observational study, treatment with cholecalciferol booster therapy, regardless of baseline serum 25(OH)D levels, appears to be associated with a reduced risk of mortality in acute in-patients admitted with COVID-19.